A novel treatment strategy with personalized cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma, according to ground-breaking results reported ...
Sep 11, 2022
0
24
The statistics for pancreatic cancer are sobering. With a five-year survival rate of only 9%, incidence of the most common type, pancreatic ductal adenocarcinoma (PDAC), is growing and projected to be the second cause of ...
Sep 8, 2022
0
34
Urothelial carcinoma (UC) is one of the most common malignancies genitourinary cancers, including upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB).
Jul 26, 2022
0
7
A research group at Leipzig University Hospital, led by Professor Ulrich Hacker, together with scientists from Masaryk University in Brno, Czech Republic, has investigated what influences the life expectancy of patients with ...
Jul 11, 2022
0
36
The addition of procarbazine, lomustine, and vincristine (PCV) chemotherapy to radiation therapy (RT) was shown to lengthen both disease control and survival relative to RT alone as first-line therapy following surgery on ...
Jun 28, 2022
0
36
In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses and outcomes in undifferentiated pleomorphic sarcoma (UPS) and recurrent dedifferentiated liposarcoma (DDLPS), ...
Jun 6, 2022
0
11
An enzyme that has been identified as instrumental in the progression of many types of cancer is meeting its match in inhibitors synthesized and evaluated by University of Colorado (CU) Cancer Center researchers.
Apr 7, 2022
0
23
Researchers at The University of Texas MD Anderson Cancer Center have discovered that two distinct classes of cancer-associated fibroblasts (CAFs) accumulate in the pancreatic tumor microenvironment and play opposing roles ...
Mar 29, 2022
0
6
Among patients with hormone receptor-positive breast cancer treated with an aromatase inhibitor plus palbociclib (Ibrance), those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled ...
Dec 9, 2021
0
3
Results from a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center showed that treatment with belzutifan, a small-molecule inhibitor of hypoxia-inducible factor (HIF)-2a, achieved strong ...
Nov 24, 2021
0
21
